Nycomed reports healthy imaging growth

By staff writers

March 1, 2000 --

Nycomed Amersham's medical imaging business reported healthy growth in revenue and operating profit for 1999 (end-December 31), the Buckinghamshire, U.K. pharmaceutical company reports.

For the year, Nycomed's imaging business recorded sales of $1.15 billion, compared with $1.05 billion the year before, representing 9% growth (including the effects of exchange rate fluctuations). The division's operating profit was $280.9 million, up 4%.

Nycomed Amersham enjoyed growth across all its product lines, and saw particularly strong results in the second half of the year. Nycomed's x-ray contrast products recorded revenues of $421.4 million, up 5%, while MRI contrast agents saw a 20% sales increase, to $84.4 million. The company's radiopharmaceutical business produced revenue of $405.2 million, and its radiation therapy products generated $99.5 million in sales.

By staff writers
March 1, 2000

Copyright © 2000


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking